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A B S T R A C T
Synthesis and biological evaluation of a novel library of fused 1,2,3-triazole derivatives are described. The in-
house developed multicomponent reaction based on commercially available starting materials was applied and
broad biological screening against various viruses was performed, showing promising antiviral properties for
compounds 14d, 14n, 14q, 18f and 18i against human coronavirus 229E. Further in silico studies identified the
key molecular interactions between those compounds and the 3-chymotrypsin-like protease, which is essential to
the intracellular replication of the virus, supporting the hypothesis that the protease is the target molecule of the
potential antiviral derivatives.
Coronaviruses are single-stranded RNA viruses associated with mild
to severe respiratory symptoms. Human coronaviruses (HCoV) strains
HCoV-229E and HCoV-OC43 were first described in the 1960s as causes
for respiratory tract infections in humans, including common cold and
pneumonia.1 In 2002–2003, a new human coronavirus, named SARS-
CoV, was identified as the etiological agent for the global outbreak of
severe acute respiratory syndrome (SARS), which caused the death of
over 800 individuals among 8000 cases worldwide, representing a
fatality rate of almost 10%.2–4 Since then three additional coronaviruses
have been recognized. Initially, HCoV-NL635 and HCoV-HKU1,6 were
reported causing acute respiratory diseases of lower severity compared
to the SARS-CoV and more recently, Middle East respiratory syndrome
(MERS-CoV) causing lethal respiratory diseases.7,8 To date, there are no
approved antiviral drugs or vaccines available for the prevention and/
or treatment of SARS-like viruses making the development of effective
antiviral agents an imperative need.9
Coronaviruses express two proteases, a papain-like protease (PLpro)
and a 3-chymotrypsin-like protease (3CLpro). The 3CLpro enzyme, also
referred to as Main protease (Mpro), is essential to the intracellular viral
replication, making it an attractive target for the development of novel
inhibitors.10 Reports in the literature classify potential antiviral com-
pounds into two main categories: i) the peptidomimetics (Fig. 1A) and
ii) small molecule-based inhibitors (Fig. 1B) presenting both activities
in μM and nM range. Despite the satisfying initial results, the majority
of those promising compounds did not proceed to clinical studies due to
nonideal physicochemical properties.9
References on non-peptidic inhibitors accentuate the presence of the
benzotriazole group. The importance of this benzotriazole motif relies
on the formation of key interactions with the catalytic dyad, Cys145
and His41, of the 3CLpro active site.11 Considering our interest in the
chemistry of 1,2,3-triazole bioactive molecules and their interesting
binding mode, we wanted to prepare a novel library of fused 1,2,3-
triazoles and subsequently determine their biological activity.
Here, we reported our preliminary results on the development of a
novel series of fused 1,2,3-triazole compounds and their potential an-
tiviral activity. For this purpose, we implemented the multicomponent
reaction developed within our group, which resulted in a plethora of
1,2,3-triazole derivatives in a single step starting from readily available
enolizable carbonyl compounds, primary amines and 4-nitrophenyl
azide. In general, the method proceeds via an equilibrium of imine/
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enamine followed by [3+ 2] cycloaddition with the azide.12 This leads
to a triazoline intermediate which after elimination of 4-nitroaniline
results in the final fused 1,2,3-triazole analogues.
The synthesis, presented in Scheme 1, began by following a general
method to generate the oxopiperidine carboxylate intermediate which
involves Michael addition of aniline onto ethyl acrylate followed by an
intramolecular Dieckmann condensation.20 Subsequent nucleophilic
substitution with benzyl bromide provided the starting material 11 in
65% overall yield. Once 11 was obtained, we proceeded for the fused
triazole formation using a collection of primary amines and 4-ni-
trophenyl azide (PNA, 13).
We commenced our investigations with benzylic amines bearing
both electron-donating functional groups, (Table 114b, c) and electron-
withdrawing groups, (Table 114d–j). Both families were obtained in
moderate to good yields.
Further analysis using heterocyclic and aliphatic derivatives 14k–p
proved the applicability of these substituents under the high tempera-
ture conditions used in this reaction (Table 1). Furthermore, we ex-
amined the influence of the introduction of a fluoro group on the benzyl
bromide on the reactivity (Table 1, entries 17 and 18), which demon-
strated that there is no effect on the outcome of the reaction.
A second series of fused 1,2,3-triazole analogues was prepared
based on the previously described multicomponent method, starting
from N-phenyl-4-piperidone material 17 which in turn was synthesized
according to Buchwald-Hartwig Pd-catalyzed amination of different
aryl bromides, presented in Scheme 2.21 We initially examined the
scope of this reaction with respect to primary amines. As we would
expect based on the aforementioned results, we managed to synthesize
an adequate number of examples in good to excellent yields (18a–d).
Furthermore, the presence of electron withdrawing substituents on the
aryl bromides was explored (18e–l). The results are summarized in
Table 2.
The compounds were evaluated against a broad variety of viruses
including HIV-1 (strain IIIB), HIV-2 (strain ROD) in MT-4 cells, herpes
simplex virus type 1 (strain KOS), herpes simplex virus type 2 (strain
G), herpes simplex virus type1 TK- (KOS) ACV res, vaccinia virus, adeno
virus-2 and coronavirus (229E) in HEL cells and their inhibitory activity
was compared to that of reference compounds as zidovudine, brivudine,
Fig. 1. Representative A) peptidic13 and B) small molecule SARS-CoV 3CLpro inhibitors.14–19
Scheme 1. Synthetic pathway towards derivatives 14a–r. Reagents and conditions:(a) AcOH, CuCl, 24 h, 110 °C, 55%, (b) NaH, Toluene, EtOH, 6 h, 100 °C, 90%, (c)
BnBr, K2CO3, THF, 6 h, 70 °C, 65%,(d) Toluene, 18 h, 100 °C.
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cidofovir, acyclovir, ganciclovir, zalcitabine, alovudine and Urtica
dioica agglutinin (UDA), respectively. All compounds were inactive
towards all tested viruses, while 14d (EC50= 8.95 µM), 14n
(EC50= 9.45 µM), 14q (EC50= 9.45 µM), 18f (EC50= 8.90 µM) and
18i (EC50= 11.95 µM) showed moderate activity against human cor-
onavirus (229E), but all approximately 50 fold lower than the activity
observed with UDA (EC50= 0.2 µM). No alterations of the normal cell
morphology in confluent HEL cell cultures was observed at concentra-
tions up to 100 µM (data not shown). The selectivity index (SI) (MCC/
EC50 ratio) was> 8 for all active compounds.
To determine the structure-activity relationship (SAR) for the syn-
thesized library of fused 1,2,3-triazoles, it is of utmost importance to
identify the key intermolecular contacts involved in the non-covalent
interaction between 3CLpro and the structurally diverse inhibitors. With
this aim, several molecular modeling techniques, including molecular
docking, molecular dynamics, free energy of binding analyses and in-
termolecular interaction scanning, were applied in the search of such
SAR knowledge. In a first stage, previously reported 3CLpro non-cova-
lent inhibitors were modeled in order to define the key intermolecular
interactions required for enzyme inhibition, while in a second stage the
in silico analysis was extended to the family of fused 1,2,3-triazoles
presented in this report.
The catalytic activity of 3CLpro has been well characterized, with
extensive details regarding the structure of this enzyme and the corre-
sponding catalytic site. In this respect, it is known that the active site is
located within domains I and II, in which a catalytic dyad consisting of
residues Cys145 and His41 is located.11 It has also been previously
reported that the catalytic site of 3CLpro exhibits a stereoselective re-
cognition of non-covalent inhibitors.18 In this context, our molecular
modeling protocols initiated with the exploration of the binding mode,
intermolecular interaction pattern and stereoselectivity of the non-
covalent inhibitor of 3CLpro deposited in the Protein Databank under
the code 3V3M. Both enantiomers of the bound ligand were docked
within the catalytic site, and as can be seen in Fig S1a,b, the R en-
antiomer resulted in an identical interaction pattern to that observed in
the experimentally obtained crystal. The ligand binding is stabilized by
several hydrophobic and hydrogen bond (HB) interaction, of which
those with Glu166, His163 and Gly143 are of particular relevance.
Noteworthy, the S enantiomer was also able to establish several hy-
drophobic interactions, but was not able to establish HB with Glu166
and His163. Taking into account that it has been previously reported
that only the R enantiomer is active,18 this finding suggests that the
establishment of interactions with Glu166 and His163 constitutes a
critical feature to inhibit the catalytic activity of the enzyme. To further
study the persistence of these HB interactions, the intermolecular
complexes were subjected to molecular dynamics (MD) analysis, with
Table S1 presenting the persistence value (%) for each HB as calculated
from the MD trajectories. As can be seen in Table S1, entry 1, the R
enantiomer was able to maintain in relatively high frequencies the HB
interactions with Glu166, His163 and Gly143, while the S enantiomer
rearranged its binding to contact only Glu166 (60% persistence). Our
findings not only validate the molecular modeling workflow we de-
veloped (i.e. the crystallographic binding pose was reproduced), but
also strongly suggests that at least two stable electrostatic interactions
within the active site are required for effective 3CLpro inhibition.21
To further study this hypothesis, a set of 12 previously reported
3CLpro inhibitors containing a fused 1,2,3 triazole ring and exhibiting a
wide range of inhibitory activities (i.e. between 51 and 26000 nM,
Tables S3 and S5), was subjected to our molecular modeling workflow.
The lowest energy binding mode obtained for TS8 was in agreement
with the reported crystallographic structure (Fig. S3d and pdb code
4MDS, respectively), further supporting an adequate parametrization
and simulation conditions of the molecular modeling protocol. From
inspection of the corresponding lowest energy docked poses for the
whole set of compounds (Figs. S2–S4), we observed that all these in-
hibitors were indeed able to establish the two HB previously described
for 3V3M, i.e. one with the backbone of Glu166 and another one with
the side chain of His163. In these binding modes, the triazole ring is
positioned in the proximity of the catalytic dyad. From the MD
Table 1
Molecular structures, yield and biological activity against coronavirus (229E) of
derivatives 14a–r.
Entry Compound ID R1 R2 Yield EC50 (μM)a
1 14a 80% >100
2 14b 85% >100
3 14c 65% >100
4 14d 80% 8.95
5 14e 58% >100
6 14f 80% >100
7 14g 67% >100
8 14h 48% >100
9 14i 30% >100
10 14j 73% >100
11 14k 55% >100
12 14l 56% >100
13 14m 85% >100
14 14n 80% 9.45
15 14o 57% >100
16 14p 51% >100
17 14q 50% 9.45
18 14r 60% >100
a Concentration required to reduce virus-induced cytopathogenicity by 50%.
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simulations and the quantification of the persistence of the above
mentioned hydrogen bond interactions (Table S1, entries 3–14), we
observed that all the compounds maintained the hydrogen bonds re-
quired for the inhibition of 3CLpro in high frequencies, and in particular
that with Glu166. It is noteworthy that inhibitors that are en-
antiomerically pure and exhibiting submicromolar activities main-
tained high frequencies of HB with Glu166 and His163. In particular,
TS-1, which is by far the most potent compound within the training set,
exhibited also a single cluster of docked poses, suggesting not only an
efficient pharmacodynamic interaction with 3CLpro, but also an ade-
quate conformational preorganization that is compliant with the cor-
responding bioactive conformation.
Compounds 14a–r and 18a–l were subjected to the molecular
modeling workflows in order to study whether 3CLpro may represent a
plausible molecular target for their observed antiviral activity. Figs. S5
and S9 shows the lowest energy binding modes to 3CLpro found for
compounds 14a–r. When the docked poses corresponding to the
bioactive derivatives are observed (i.e. 14d and 14n, Figs. S5d, S8b,
respectively), it can be seen that they establish the two HB interactions
with Glu166 and His163, positioning also the triazole ring in the
proximities of the catalytic dyad. As it was discussed in previous sec-
tions, this interaction pattern is required for the inhibition of 3CLpro
catalytic activity, suggesting that this enzyme may be the antiviral
target of these fused 1,2,3-triazoles. Further analysis by MD also
showed that these interactions are maintained throughout the simula-
tion, further supporting their bioactivities (Table S2, entries 4, 14 and
17). In contrast, the fused triazole derivatives that did not exhibited
antiviral activities in infected cells, did not establish these two HB in-
teractions in the lowest energy binding pose, or were not able to form
them during the simulation trajectory when subjected to MD assays.
Compounds 14c and 14m constitute two exceptions to this behavior,
both of them bearing a methoxy substituent on the para position of the
phenyl ring substituting the triazole central scaffold. These two com-
pounds were able to establish and maintain the HB interaction pattern
required for 3CLpro inhibition, (Table S2, entries 3 and 13) but did not
exhibit antiviral activity. This fact may be due to a disfavorable en-
tropic contribution upon binding to the 3CLpro catalytic site, since in
order to maintain the interaction with His163, the rotation of the
methoxy group is constrained within a dihedral angle of 10 Å. Clearly,
this entropic cost is not present for the bioactive analogue bearing a
fluorine atom in the para position (14d).
When derivatives 18a–l were analyzed (Figs. S10–S12), a similar
behavior was observed, with the derivatives exhibiting antiviral activity
(i.e. 18f and 18i) being able to establish two stable HB interactions
within the catalytic site of 3CLpro (Figs. S11b and S12a). In particular,
derivative 18f is anchored within the catalytic site through a stable
interaction with His163, with two additional interactions being estab-
lished with Glu166 and Thr25. Regarding the interaction of 18i, this
compound establishes stable HB contacts with both Glu166 and His163,
while further anchoring to residue Gln189. As a result, both compounds
positioned the fused triazole scaffold in the vicinity of the catalytic
dyad which is consistent with blocking the protease activity of the
enzyme. Finally, when the interaction patterns of the inactive com-
pounds within the series 18a–l were analyzed, we found that all of
them failed to establish the two required HB interactions within the
catalytic site of the enzyme.
Scheme 2. Reagents and conditions: (a) Pd(OAc)2, XPhos, NaO-t-Bu, Toluene/t-BuOH (5:1), 18 h, 120 °C, 65%, (b) aq. HCl (5 N), 3 h, 100 °C, 45%,(c) Toluene, 18 h,
100 °C.
Table 2
Molecular structures, yield and biological activity against coronavirus (229E) of
derivatives 18a–l.
Entry Compound ID R R’ Yield EC50 (μM)a
1 18a H 85% >100
2 18b 74% >100
3 18c 90% >100
4 18d 48% >100
5 18e -CF3 90% >100
6 18f 85% 8.9
7 18g 85% >100
8 18h 89% >100
9 18i 85% 11.95
10 18j 89% >100
11 18k -F 91% >100
12 18l 57% >100
a Concentration required to reduce virus-induced cytopathogenicity by 50%.
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In conclusion, we have succeeded in synthesizing a novel library of
fused 1,2,3-triazoles using the in-house developed multicomponent
reaction. The library was subjected to in vitro analysis using a broad
variety of viruses to determine their antiviral properties and to in silico
studies to determine the interactions with 3CLpro. Compounds 14d,
14n, 14q, 18f and 18i showed moderate activity against coronavirus
229E. A molecular modeling work flow was developed based on pre-
viously reported 3CLpro non-covalent inhibitors and helped the identi-
fication of key molecular interactions. Application of this model to our
library, supports that the antiviral activity is mediated through the
inhibition of 3CLpro. Additional studies on the structure-activity re-
lationship will enable us to prepare new fused 1,2,3-triazole derivatives
with enhanced antiviral properties.
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